Market Research Blog – Page 364 – New Product Development

Global Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market Poised for Significant Growth, Projected to Reach USD 4.89 Billion by 2033

The global focal segmental glomerulosclerosis (FSGS) therapeutics market is on track to achieve remarkable growth, with projections indicating a market value of USD 4.89 billion by 2033, up from USD 3 billion in 2023. This expansion represents a CAGR of 5% from 2023 to 2033, reflecting the growing demand for effective treatment solutions for this rare kidney disorder.

The historical data showcases steady growth, with the market registering a CAGR of 3.5% from 2018 to 2022. This upward trajectory underscores the increasing recognition of the disease and the need for advanced therapeutic options.

Market Dynamics:

Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney condition that leads to scarring of the glomeruli, the filtering units within the kidneys. The increasing prevalence of FSGS globally is a major driver of market growth. However, as the condition is relatively rare, the therapeutics market remains niche, requiring continued innovation and investment in research and development.

Current treatment options include:

Corticosteroids: Prednisone is widely used to reduce kidney inflammation and decrease proteinuria, a hallmark symptom of FSGS.
Immunosuppressive Drugs: Medications like cyclosporine play a crucial role in controlling the immune system to mitigate kidney damage.

While these treatments are effective in managing symptoms and slowing disease progression, the market is ripe for the development of novel therapies that address unmet clinical needs.

Growth Opportunities:

Advancements in precision medicine and the introduction of targeted biologics are expected to further propel the market. Additionally, increased awareness among healthcare professionals and patients, combined with robust funding for research initiatives, is likely to unlock new avenues for growth in the FSGS therapeutics market.

Future Outlook:

“The significant growth trajectory of the FSGS therapeutics market highlights the urgent need for innovative solutions to combat this debilitating condition. With advancements in immunotherapy and the potential for gene-based therapies, the future looks promising for both patients and healthcare providers,” stated FMI.

Key Takeaways from the Market Study:

From 2018 to 2022, the Focal Segmental Glomerulosclerosis (FSGS) Therapeutics market grew at a CAGR of 3.5%.
The global Focal Segmental Glomerulosclerosis (FSGS) Therapeutics market is expected to grow with a 5% CAGR during 2023 to 2033.
As of 2033, the Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market is expected to reach US$ 4.89 Billion.
According to the FMI analysis, the immunosuppressive agents segment accounts for the largest market share.
North America is expected to possess 40% market share for the Focal Segmental Glomerulosclerosis (FSGS) Therapeutics market.
The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

Rising Demand for Market Data: Our Full Report Offers Deep Insights and Trend Analysis!

Market Competition:

Key players in the market include companies such as Competition Deep Dive, Beckman Coulter Inc., Baxter International Inc., ChemoCentryx Inc., Dimerix Ltd, Medtronic PLC, Pfizer Inc., Mylan N.V., Amgen Inc., AstraZeneca plc along with healthcare providers and technology companies among other global players.

In May 2022, Travere Therapeutics, Inc. (NASDAQ: TVTX) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan to treat IgA nephropathy (IgAN) and has granted Priority Review. Travere Therapeutics is looking forward to working with the FDA throughout the review process to potentially deliver sparsentan to the IgA nephropathy community.

The NDA submission for sparsentan is based on results from the ongoing Phase 3 PROTECT Study, which is one of the largest interventional studies conducted in IgAN to date. The study evaluated sparsentan in 404 patients with persistent proteinuria and met its pre-specified interim primary efficacy endpoint, which measured changes in proteinuria compared to the active control irbesartan.

Key Segments Profiled in the Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Industry Survey:

Disease Type:

Primary FSGS
Secondary FSGS

Drug Class:

Corticosteroids
Immunosuppressive Drugs
Plasmapheresis
ACE Inhibitors and ARBs
Diuretics

Treatment:

Drug Therapy
Dialysis
Kidney Transplant

Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Hepatic Encephalopathy Treatment Market on a Robust Growth Trajectory: Expected to Reach USD 2971.51 Million by 2033 registering a CAGR of 6.5%

The global hepatic encephalopathy treatment market is set to achieve significant growth, with projections indicating an increase from USD 1583 Million in 2023 to USD 2971.51 Million by 2033, reflecting a CAGR of 6.5% during the forecast period. The market witnessed a moderate growth rate of 3.9% CAGR during the historical period of 2018 to 2022, which is now accelerating due to a surge in liver-related disorders worldwide.

Key Market Drivers:

The rise in liver diseases, including cirrhosis and non-alcoholic fatty liver disease (NAFLD), is a primary factor fueling market growth. As hepatic encephalopathy stems from the liver’s inability to eliminate toxins from the bloodstream effectively, leading to toxin buildup in the brain, the demand for comprehensive treatment solutions continues to grow.

Understanding Hepatic Encephalopathy:

Hepatic encephalopathy is a severe condition that can range from mild to life-threatening, characterized by symptoms such as:

Cognitive dysfunction: Confusion and personality changes.
Neurological issues: Tremors and loss of motor control.
Severe outcomes: Potential progression to coma in advanced stages.

Effective management of HE involves addressing its root causes, primarily liver diseases like cirrhosis. Treatments include:

Medication: To reduce toxin levels in the bloodstream.
Dietary modifications: Tailored to support liver health.
Lifestyle changes: Including alcohol cessation and regular medical monitoring.

Future Outlook:

With advancements in medical research and increased awareness, the HE treatment market is poised for steady growth. Pharmaceutical innovations and comprehensive management strategies targeting liver health will play a critical role in shaping the market landscape.

As the prevalence of liver disorders continues to rise, so does the importance of effective hepatic encephalopathy treatments. The robust growth projected for the global HE treatment market underscores the urgency and potential for innovation in managing this critical condition, paving the way for improved patient outcomes and a healthier global population.

Accelerated Market Demand: Find Comprehensive Insights and Trends in Our Full Report!

Key Takeaways from the Market Study:

The Hepatic encephalopathy treatment market is expected to grow at a value of 6.5% CAGR in the forecast period 2023-2033
Hospital pharmacies are expected to hold 49% of the market share in 2023 for Hepatic encephalopathy treatment market.
North America is expected to possess 44% market share for Hepatic encephalopathy treatment market in 2023.
Asia Pacific Hepatic encephalopathy treatment market size is expected to possess 39% market share in 2023.

“The Hepatic Encephalopathy Treatment Market is also being driven by the increasing adoption of combination therapies for HE.” states an FMI analyst

Competitive Landscape:

Key players in the hepatic encephalopathy treatment market are Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline plc., Pfizer Inc., ASKA Pharmaceutical Co., Ltd., Bausch Health, Johnson & Johnson Services, Inc., Janssen Global Services, Takeda Pharmaceutical Company Limited, Merck & Co., Inc.

Mallinckrodt Pharmaceuticals has developed and marketed several medications for the treatment of Hepatic Encephalopathy that include Ofirmev and Terlipressin (Glypressin) injection. In addition to these medications, Mallinckrodt Pharmaceuticals has also sponsored clinical research into the treatment of HE, with a focus on developing new treatments and improving the understanding of the condition.
Salix Pharmaceuticals has developed Xifaxan (rifaximin) tablets. Xifaxan is an antibiotic medication that works by reducing the levels of bacteria in the gut, which can help reduce the production of toxins that contribute to the development of HE.

Key Segments Profiled in the Hepatic Encephalopathy Treatment Industry Survey

Drug Class:

Antibiotics
Laxatives
L-ornithine
L-aspartate

Diagnosis:

Blood Tests
CT Scan
Liver Functioning Tests

Route of Administration:

Oral
Injectable
Intravenous
Others

Distribution Channel:

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

About Future Market Insights (FMI)

Contact Us:

Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market to reach USD 6.82 billion by 2033, expanding at a CAGR of 6.9%: FMI Report

The global chimeric antigen receptor (CAR) T-Cell therapy market is witnessing remarkable growth, with its market value surging from USD 2.54 billion in 2022 to an anticipated USD 3.5 billion in 2023, and further projected to reach a staggering USD 6.82 billion by 2033, according to recent industry reports. This represents a compound annual growth rate (CAGR) of 6.9% during the forecast period (2023–2033).

Such unprecedented growth underscores the increasing adoption of this revolutionary cancer treatment, driven by technological advancements and the rising demand for personalized medicines. Historical data also reflects a strong performance, with the market registering a CAGR of 7% between 2018 and 2022.

Revolutionizing Cancer Treatment: The CAR T-Cell Therapy Advantage:

CAR T-cell therapy represents a groundbreaking advancement in the field of immunotherapy, utilizing a patient’s own immune system to combat cancer. This innovative treatment involves a multi-step process:

Collection of T-Cells: T cells, a type of white blood cell pivotal to the immune system, are extracted from the patient.
Genetic Modification: These cells are genetically engineered to express a chimeric antigen receptor (CAR) on their surface, enabling them to recognize specific proteins on cancer cells.
Reinfusion: The modified T-cells are then reinfused into the patient’s bloodstream, where they target and destroy cancer cells with precision.

This targeted approach offers hope for patients battling complex cancers, positioning CAR T-cell therapy as a beacon of innovation in oncology.

Driving Forces Behind Market Expansion:

The growth trajectory of the CAR T-cell therapy market can be attributed to:

Technological Innovations: Continuous advancements in genetic engineering and cell modification techniques have enhanced the efficacy and safety of CAR T-cell therapies.
Demand for Personalized Medicine: The increasing emphasis on individualized treatment solutions for cancer patients has propelled the adoption of CAR T-cell therapy globally.

A Promising Future for Oncology Care:

With its transformative potential, CAR T-cell therapy is poised to redefine cancer care by offering a personalized and effective treatment option for patients. This dynamic market presents significant opportunities for stakeholders, including biopharmaceutical companies, healthcare providers, and researchers, to drive innovation and improve patient outcomes.

As the CAR T-cell therapy market continues to flourish, it is set to play a pivotal role in advancing global cancer care, bringing hope to millions of patients worldwide.

Soaring Demand for Market Information: Uncover Detailed Trends and Insights in Our Report!

Key Takeaways from the Market Study:

The Chimeric antigen receptor (CAR) T-Cell therapy market is expected to grow at a CAGR of 6.9% in the forecast period 2023 to 2033.
By type, Yescarta is expected to hold 45% of the market share in 2023 for Chimeric antigen receptor (CAR) T-Cell therapy market.
North America is expected to possess 45% market share for Chimeric antigen receptor (CAR) T-Cell therapy market in 2023.
Europe Chimeric antigen receptor (CAR) T-Cell therapy market size is expected to possess 39% market share in 2023.

“The increasing incidence of cancer, rising demand for personalized medicine, and advancements in CAR T-cell therapy are some of the major factors driving the growth of the market,” states an FMI analyst.

Competitive Landscape:

Key players in the Chimeric antigen receptor (CAR) T-Cell therapy market are Abbott Laboratories, Baxter International Inc., Becton, Dickinson and Company, Boston Scientific Corporation, Fresenius SE & Co. KGaA, Johnson & Johnson, Medtronic PLC, Novartis AG, Endo International PLC and Pfizer Inc.

BD has contributed to CAR T-cell therapy is through its flow cytometry technology, which is used to monitor the manufacturing and quality control of CAR T-cell therapies. Flow cytometry is a technique that allows researchers and clinicians to analyze and sort individual cells based on their physical and chemical characteristics. BD offers a range of flow cytometry instruments and reagents that are used to monitor the T-cells used in CAR T-cell therapy, as well as the cancer cells targeted by these therapies.
Boston Scientific has contributed to CAR T-cell therapy through its interventional oncology products. These products are designed to treat cancer through minimally invasive procedures, such as tumor ablation or embolization. While these procedures are not directly related to CAR T-cell therapy, they can be used to manage complications that may arise during or after CAR T-cell treatment, such as bleeding or swelling in the liver.

Key Segments Profiled in the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Survey

By Type:

Abecma
Breyanzi
Kymriah
Tecartus
Yescarta
Others

By Application:

Leukemia
Lymphoma
Multiple Myeloma
Autoimmune Disorders
Other Application

By End User:

Hospitals
Cancer Care Treatment Centers

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East & Africa

About Future Market Insights (FMI)

Contact Us:

Global Crohn’s Disease Treatment Market Set to Reach USD 17.80 Billion by 2033 at a steady 4.3% CAGR, Driven by Rising Incidence and Demand for Advanced Therapies | FMI

The global market for Crohn’s disease (CD) treatment is on a significant growth trajectory, projected to reach approximately USD 17.80 billion by the end of 2033. This substantial increase, up from USD 11.68 billion in 2023, reflects a compound annual growth rate (CAGR) of 4.3%, according to a comprehensive report by Future Market Insights.

The burgeoning prevalence of Crohn’s disease and ulcerative colitis across the globe serves as the primary driver of this market expansion. As public awareness and medical understanding of these chronic inflammatory bowel diseases continue to rise, so does the demand for effective treatment options. This trend is expected to significantly bolster the market over the next decade.

With advancements in medical research and pharmaceutical innovations, the treatment landscape for Crohn’s disease is evolving rapidly. Patients are increasingly seeking newer, more effective therapies that offer better management of symptoms and improved quality of life. This heightened demand is prompting pharmaceutical companies to invest heavily in research and development, aiming to introduce novel therapeutic solutions that can address the unmet needs of patients.

The Future Market Insights report emphasizes the role of cutting-edge biologics and biosimilars, alongside conventional therapies, in shaping the future of Crohn’s disease treatment. As these advanced treatments become more accessible, they are likely to contribute to the overall growth of the market.

In addition to the rising patient population, other factors such as improved diagnostic capabilities, growing healthcare infrastructure, and increased healthcare spending are also playing a pivotal role in the market’s expansion. As healthcare systems around the world become more equipped to diagnose and manage Crohn’s disease, the market is poised for continued growth.

Industry experts anticipate that the market’s steady growth will also drive strategic partnerships and collaborations among key players, fostering innovation and improving patient outcomes. The Future Market Insights report serves as a valuable resource for stakeholders, providing insights into market trends, growth drivers, and potential challenges.

Key Takeaways from the Market Study:

The Crohn’s disease treatment market expanded historically between 2018 and 2022 at a CAGR of 3.2%.
More than $11.2 billion is presently spent on treating Crohn’s disease globally.
Immunomodulators are predicted to lead the medication type sector in 2023 with a 53% revenue share.
The hospital pharmacy sector by distribution channel will maintain the second-largest segment during the anticipated period, with a global market share of 27.3% in 2023.
From 2023 to 2033, the North American region is expected to expand at a constant CAGR of 4.9%.
From 2023 to 2033, the Asia Pacific Crohn’s Disease Treatment Market is anticipated to expand at a stable CAGR of 3.6%.

“The increasing prevalence of ulcerative colitis and Crohn’s disease along with innovative pipeline of biological therapies and medications are expected to accelerate the growth during the forecast period,” comments a Future Market Insights analyst.

Enhance Your Business Outcomes with the Strategic Insights from A Full Report Analysis!

Competitive Landscape:

Some of the top players in the global intraocular lymphoma disease market are:

Abbvie Inc.
Celgene Corporation
Genetech
Johnson & Johnson
Pfizer
Prometheus Laboratories Inc. (Nestle)
Salix Pharmaceuticals Inc.
Takeda’s Pharmaceutical Ltd
Janssen Pharmaceuticals
Biogen
AstraZeneca

Some of the recent developments in this domain are:

In 2022, AbbVie said that SKYRIZI® (risankizumab-rzaa) has received FDA approval to be used in the management of moderately to highly active Crohn’s disease. The interleukin-23 (IL-23) inhibitor SKYRIZI binds to the p19 component of IL-23 to specifically inhibit it. A variety of chronic immune-mediated disorders, including Crohn’s disease, are suspected to be related to IL-23, a cytokine implicated in inflammatory processes.
Tiziana Life Sciences, a biotechnology firm that enables breakthrough immunotherapies through innovative modes of monoclonal antibody administration, announced the start of a Phase 1b clinical study in 2022 to test foralumab enteric-coated capsules orally delivered in people who have mild to moderate Crohn’s Disease (CD). A unique method of inducing an anti-inflammatory immune reaction by site-targeted immunomodulation in the intestine is oral administration of foralumab.

Key Segments Covered in the Crohn’s Disease Treatment Market Report:

By Drug Type:

Antibiotics
Amino Salicylates
Corticosteroids
Immunomodulators
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

About Future Market Insights (FMI)

Contact Us:

Global AL Amyloidosis Therapeutics Market Set for Remarkable Growth, Projected to Reach USD 4.56 Billion by 2033 rise at a 7.3% CAGR

Future Market Insights, a leading market research firm, has unveiled a comprehensive report forecasting significant expansion in the global AL amyloidosis therapeutics market. According to the report, the market is poised to grow from USD 2.25 billion in 2023 to a remarkable USD 4.56 billion by 2033, registering a robust Compound Annual Growth Rate (CAGR) of 7.3%.

AL amyloidosis is a rare and serious condition characterized by the abnormal accumulation of amyloid proteins in various organs and tissues. This protein build-up can lead to organ damage and a decline in function, posing substantial health challenges. Common symptoms include weight loss, weakness, fatigue, difficulty breathing, joint pain, and distinct skin manifestations such as redness and spider veins.

The rising incidence of AL amyloidosis, particularly among the aging population, is a primary driver of the growing demand for effective therapeutic interventions. As the prevalence of this condition increases, the need for advanced treatments and innovative therapies becomes more critical.

The projected growth of the AL amyloidosis therapeutics market underscores the urgency and necessity of addressing this debilitating disease. The expansion is expected to bring new opportunities for healthcare providers, pharmaceutical companies, and researchers dedicated to improving patient outcomes and enhancing the quality of life for those affected by AL amyloidosis.

Key Takeaways from the Market Study:

The market for treatments for AL amyloidosis expanded at a CAGR of 5.1% from 2018 to 2022.
More than USD 2.1 billion is presently spent on treating AL amyloidosis worldwide.
Chemotherapy is predicted to command the market in 2023 with a 53% revenue share.
The hospital pharmacy sector by distribution channel will hold the second-largest segment during the anticipated period, with a 25% worldwide market share in 2023.
From 2023 to 2033, the North American region is expected to expand at a constant CAGR of 7.9%.
From 2023 to 2033, the Asia Pacific AL amyloidosis therapies market is anticipated to expand at a stable CAGR of 7.6%.

“Due to factors including rising incidence as well as the anticipated introduction of innovative therapeutics throughout the projected period, the market for AL amyloidosis therapeutics is predicted to rise favorably.” comments a Future Market Insights analyst.

Increased Market Demand: Get In-Depth Analysis and Insights with Our Complete Report!

Competitive Landscape:

Janssen Pharmaceutical
Prothena
Alexion Pharmaceuticals
Oncopeptides AB
Bristol-Myers Squibb
GlaxoSmithKline Pharmaceuticals Ltd
Celgene Corp
Eidos Therapeutics, Inc.
Corino Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
Pfizer

Some of the recent developments in this domain are:

The U.S. Food and Drug Administration (FDA) approved Sorrento Therapeutics, Inc.’s experimental new drug application for STI-6129, a CD38-targeting monoclonal antibody combination, in 2020. Sorrento Therapeutics is currently working on a number of technological platforms, along with a CD38-specific antibody found in its completely human G-MABTM antibody library, its own pharmacological payload Duostatin 5, as well as its site-specific C-LOCK coupling technology. These platforms are all used by STI-6129.

Key Segments Covered in the AL amyloidosis therapeutics market Report:

By Treatment:

Chemotherapy
Supportive Care
Surgery
Stem Cell Transplant
Targeted Therapy

By Drugs:

Transthyretin Transport Inhibitor
Immunomodulatory Drugs
Monoclonal Antibodies
Proteasome Inhibitors
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East & Africa

About Future Market Insights (FMI)

Contact Us:

Global Post-Traumatic Stress Disorder Treatment Market to reach USD 27.37 billion by 2033; Antidepressants to be Most Consumed: FMI Report

The global post-traumatic stress disorder treatment market is set for significant growth, with its valuation expected to climb from USD 16.8 billion in 2023 to an impressive USD 27.37 billion by 2033, reflecting a robust CAGR of 5% during the forecast period from 2023 to 2033. This surge is attributed to the continuous innovation in therapeutic approaches and the increasing global prevalence of PTSD.

Historically, from 2018 to 2022, the PTSD treatment market registered a moderate growth rate of 3.3% CAGR, setting the stage for the accelerated expansion now anticipated. Advances in pharmacological and non-pharmacological therapies, alongside growing awareness and diagnosis rates, are key drivers of this upward trajectory.

According to the National Center for PTSD, approximately 7-8% of the US population will experience PTSD at some point in their lives, with higher rates among military veterans and individuals who have experienced sexual assault or other types of trauma. The COVID-19 pandemic has also been identified as a potential driver of PTSD, with healthcare workers, frontline responders, and individuals who have been directly affected by the virus at increased risk.

There is also a growing focus on the use of digital therapeutics and other non-pharmacological interventions for the treatment of PTSD. One example is the use of virtual reality exposure therapy (VRET), which has shown promising results in reducing PTSD symptoms by allowing individuals to confront their trauma in a safe and controlled environment. Several companies, including Limbix and Psious, are developing VRET platforms for the treatment of PTSD and other mental health conditions.

Key Takeaways from the Market Study:

The post-traumatic stress disorder (PTSD) treatment market is expected to grow at a value of 5% CAGR in the forecast period 2023 to 2033.
By drug class, antidepressants are expected to hold 41% of the market share in 2023 for post-traumatic stress disorder (PTSD) treatment market.
North America is expected to possess 43% market share for post-traumatic stress disorder (PTSD) treatment market in 2023.
Europe post-traumatic stress disorder (PTSD) treatment market size is expected to possess 42% market share in 2023.

“As the prevalence of PTSD continues to rise, the need for effective and accessible treatments will only become more pressing. While there is still much work to be done, the growing focus on PTSD treatment is a positive step forward in improving the lives of individuals affected by this debilitating condition,” states an FMI analyst.

High Demand for Market Insights: Discover Comprehensive Trends in Our Full Report!

Competitive Landscape:

Key players in the post-traumatic stress disorder (PTSD) treatment market are Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceutical Development & Commercialization, Inc., Bionomics Limited, Merck KGaA, Pfizer Inc., Aurobindo Pharma Limited, GlaxoSmithKline plc, Viatris Inc., Jubilant Pharmova

Otsuka has also partnered with the U.S. Department of Veterans Affairs (VA) to conduct a clinical trial of a medication called samidorphan (ALKS 5461) for the treatment of PTSD. Samidorphan is an opioid system modulator that is being investigated for its ability to reduce symptoms of PTSD, including anxiety, depression, and hyperarousal.
Bionomics Limited is a biopharmaceutical company that has developed a medication called BNC210, which is being investigated as a potential treatment for PTSD (Post-Traumatic Stress Disorder). BNC210 is a small molecule drug that acts as a negative allosteric modulator of the α7 nicotinic acetylcholine receptor (α7 nAChR), which is thought to play a role in the development and maintenance of PTSD symptoms.

Key Segments Profiled in the Post-Traumatic Stress Disorder (PTSD) Treatment Industry Survey:

By Drug Class:

Antidepressants
Anti-anxiety Drugs
Antipsychotics
Other Drug Classes

By Distribution Channel:

Retail Pharmacies
Online Pharmacies

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East & Africa

About Future Market Insights (FMI)

Contact Us:

Global Flat Steel Market Poised for Significant Growth, Projected to Reach USD 1,037 Billion by 2034

The global flat steel market is anticipated to expand due to factors like industrialization, urbanization, rising middle-class disposable income in developing nations, and rising global population. Steel usage in various applications, driven by cost reduction and quality improvement, is expected to boost product deployment.

Emerging economies like China and India, along with technological advancements, are expected to drive business growth in the forecast period. Flat steel is projected to gain traction in the construction and infrastructure sectors due to its versatile application and efficiency. For instance, India has seen infrastructure investments increase by over 25% since 2022, benefiting the sector.

The global flat steel market is poised for substantial growth, with its value projected to rise at a CAGR of 5.9% over the forecast period from 2024 to 2034. The market, currently estimated at USD 586 billion in 2024, is anticipated to reach an impressive valuation of USD 1,037 billion by 2034. This robust expansion is driven by increasing demand across industries such as construction, automotive, and energy, fueled by urbanization, infrastructure development, and advancements in manufacturing technologies. The versatility, cost-effectiveness, and recyclability of flat steel further bolster its adoption, positioning the industry for sustained growth in the coming decade.

Steel’s Rapid Integration into the Automotive Sector Is Due to Its Ability to Uplift Market Growth

Steel is being replaced with aluminum and composite materials in the automobile industry as a result of multiple factors aimed at improving profitability. Major portions of vehicle bodies, such as vehicle frames and shields, are made up of steel. Because of this, the automobile industry is the largest consumer of flat steel products, consisting of up to 10% of all steel produced globally. Furthermore, owing to its large ductility and dent resistance, cold rolled steel is widely used in automotive for external body and internal parts implementations. Furthermore, auto parts demanding high surface completion and impact resistance are marketing well. These aspects lead to greater flat steel expenditure, which generates growth prospects.

The construction industry’s strong demand for flat steel will push sales growth

The booming population, urbanization, and the accelerating trend of nuclearization of the inhabitants are the major drivers of construction sector expansion. Mild steel flat bar, black mild steel flat bar often used in structural stability and building project frames for roofing, stairways, sheds, and welded framework applications.

The upsurge of multiple-home ownership, rising middle-class affluence, and residence remodeling or refurbishment drive the construction sector, consequently bolstering the market. Furthermore, construction operations such as steel bridges, skyscrapers, and power grids use a lot of steel plates. Simultaneously time demand from the infrastructural development for street, highway, and rail projects is expected to rise during the forthcoming years.

Key Takeaways from the Flat Steel Market Report:

The flat steel industry is expected to reach a value of USD 1037 billion by 2034.
The market is projected to surge at a CAGR of 5.9% by 2034.
China’s flat steel market is expected to grow at a CAGR of 6.6% by 2034.
In terms of product type, the hot rolled coil segment is set to account for a 35.7% share in 2024.
Based on application, the construction segment is expected to hold a market share of 36.3% in 2024.

“Demand for flat steel is expected to rise due to expanding sectors in developed countries like Germany and the United Kingdom, driven by construction, automotive, transportation, and industrial sectors. Despite economic uncertainty, the situation is expected to stabilize in the coming years. Long-term investments in rail and canal infrastructure are further set to increase demand in Europe.” – says an Analyst at Future Market Insights (FMI).

Unlock Comprehensive Insights by Reading the Full Report Now!

Competitive Landscape

ArcelorMittal, Nippon Steel, Ezz Steel, Tata Steel, HBIS Group, Voestalpine Group, and ThyssenKrupp Steel Europe are the key service providers in the industry. Leading companies are investing in research and development to expand product lines and grow the flat steel market. They are also undertaking strategic activities like new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaborations.

To survive in a competitive market, the flat steel industry offers cost-effective items. Local manufacturing is a key business tactic used by manufacturers to minimize operational costs and benefit clients.

The flat steel industry is highly concentrated, with the leading companies accounting for nearly half of the market. Key flat steel manufacturers form strategic alliances to increase market share. Leading companies invest in research, production capacities, and strategies like partnerships, acquisitions, facility expansions, and collaborations to strengthen their presence.

Key Segmentations

By Type:

Hot rolled coil (HRC)
Cold rolled coil (CRC)
Sheets

By Application:

Construction
Automotive
Mechanical equipment

By Region:

North America
Latin America
Western Europe
Eastern Europe
South Asia
East Asia
Middle East and Africa

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Industrial Absorbent Market: Eco-Friendly Innovations Driving Growth to USD 6.5 Billion by 2034

The industrial absorbent market is poised for steady growth, projected to reach a valuation of USD 6.5 billion by 2034, with a CAGR of 3.7% from 2024 to 2034. This growth is driven by the increasing adoption of absorbents across diverse industries, including manufacturing, oil and gas, chemicals, automotive, and healthcare. These materials play a crucial role in managing spills, leaks, and waste, ensuring safety, regulatory compliance, and environmental protection. The expanding industrial base and heightened focus on sustainability are expected to further boost the demand for innovative and efficient absorbent solutions during the forecast period.

These sectors require effective spill management solutions to address spills, leaks, and drips occurring during various stages such as production, transportation, and storage. This increasing demand is propelling the growth of the industrial absorbents market.

Rising environmental concerns and a growing imperative for businesses to monitor their environmental impact are expected to drive the global industrial absorbents industry forward in the coming years. The demand for eco-friendly, high-performance absorbent materials is anticipated to fuel innovation and shape the future of spill management solutions across various sectors worldwide.

The global surge in oil and gas consumption has necessitated a significant increase in production to meet demand, raising the likelihood of oil spills during extraction activities. To safeguard both individuals and the environment from these risks, industrial absorbents are extensively utilized. There has been a notable uptick in the demand for industrial absorbents.

The projected rise in the adoption of industrial absorbents within the oil and gas sector presents manufacturers with a prime opportunity to innovate and create absorbent materials that offer both effectiveness and affordability. The exploration of new crude oil and natural gas reservoirs further amplifies the business prospects for industrial absorbent manufacturers worldwide.

Competitive Landscape

Key players in the global industrial absorbent market are strategically prioritizing collaboration, expansion, and the introduction of innovative products. The market players expanding market presence by entering new geographical regions or strengthening existing footholds through acquisitions, mergers, or partnerships.

In January 2023, ANSELL Ltd. unveiled a partnership with Vizient, Inc., focusing on room turnover essentials. Under this collaboration, Vizient members gain access to discounted rates on an extensive array of room turnover items, including absorbent floor pads, disposable linens, mops, waste bags, patient positioning straps, and turnover packs.
Decorus Europe offers a range of industrial absorbent products, including pads, socks, and pillows, designed to meet the spill containment and cleanup needs of various industries.
Meltblown Technologies Inc. produces absorbent materials using advanced manufacturing processes, offering efficient solutions for spill response and environmental protection.

Shape Your Strategy with In-Depth Insights from the Industrial Absorbent Market Report!

Key Players in the Industrial Absorbent Market

Kimberly-Clark Worldwide Inc.
3M
Johnson Matthey
ANSELL LTD
Brady Worldwide Inc.
Monarch Green Inc.
Decorus Europe
Meltblown Technologies Inc.
TOLSA
UES Promura

Industrial Absorbent Market – Key Segments

By Type:

Organic
Inorganic
Synthetic

By Material:

Clay
Diatomaceous Earth
Cellulose
Polypropylene
Others

By Region:

North America
Latin America
Western Europe
Eastern Europe
South Asia and Pacific
East Asia
Middle East and Africa

About Future Market Insights (FMI)

Contact Us:

Wood Plastic Composite Market: Rising Demand for Sustainable Materials to Drive 10.3% CAGR Growth from 2024 to 2034

Wood Plastic Composite (WPC) refers to a composite material made from a combination of wood fibers and plastic, designed to mimic the appearance of natural wood while offering enhanced durability and resistance to environmental factors. WPCs are increasingly being used in construction, decking, fencing, and other applications due to their sustainability and low maintenance requirements.

The wood plastic composite market, valued at USD 6.9 billion in 2024, is expected to grow at a CAGR of 10.3% and reach USD 18.5 billion by 2034.

Market Growth Drivers

Rising Demand for Sustainable Building Materials: As the construction industry shifts towards environmentally friendly practices, WPCs are gaining traction due to their recyclability and reduced reliance on natural wood. This shift aligns with global sustainability goals and green building certifications, driving the growth of the WPC market.
Technological Advancements: Innovations in WPC manufacturing processes and formulations have led to improved product quality, aesthetics, and performance. Advanced extrusion techniques and enhanced polymer blends are contributing to the expanding application of WPCs in various construction projects.
Increased Awareness of Environmental Impact: Growing concerns about deforestation and environmental degradation are prompting stakeholders to seek alternatives to traditional wood products. WPCs, made from recycled wood fibers and plastics, offer a viable solution by reducing waste and conserving natural resources.
Growth in Residential and Commercial Construction: The booming construction industry, particularly in emerging economies, is driving the demand for WPC products. The versatility and aesthetic appeal of WPCs make them popular choices for decking, cladding, and landscaping in both residential and commercial properties.

Opportunities

Expansion into New Applications: The WPC market presents opportunities for growth beyond traditional uses such as decking and fencing. Potential applications include interior flooring, furniture, and automotive components. Exploring these new markets can open avenues for increased revenue and market presence.
Emerging Markets: Rapid urbanization and infrastructure development in emerging economies offer significant growth prospects for WPC manufacturers. Countries in Asia-Pacific, Latin America, and Africa are witnessing increased construction activities, creating demand for sustainable and cost-effective building materials like WPCs.
Product Innovation: Continuous research and development in WPC formulations can lead to the creation of products with enhanced properties, such as improved weather resistance, fire retardancy, and aesthetic versatility. Innovating to meet specific market needs can differentiate companies and attract new customers.

Discover Detailed Findings in the Complete Report on Wood Plastic Composite Market Growth and Sustainability Trends!

Sustainable Construction Practices to Fuel Growth

Sustainable construction practices are increasingly influencing the growth of the WPC market. These practices include:

Green Building Certifications: WPCs are often used in projects seeking LEED (Leadership in Energy and Environmental Design) or similar green building certifications. Their use contributes to meeting criteria for resource efficiency and sustainable materials, making them attractive to builders and developers focused on certification goals.
Lifecycle Assessment: Incorporating WPCs in construction projects allows for a positive lifecycle assessment, as these materials often have lower environmental impacts compared to traditional wood. Highlighting the benefits of WPCs in lifecycle assessments can enhance their appeal to environmentally conscious consumers and businesses.
Circular Economy: The circular economy concept emphasizes recycling and reusing materials to minimize waste. WPCs align with this concept by utilizing recycled plastics and wood fibers. Promoting the circular economy benefits of WPCs can position them as a key player in sustainable construction practices.
Energy Efficiency: WPCs contribute to energy-efficient buildings by offering superior insulation properties compared to conventional materials. This can lead to reduced energy consumption for heating and cooling, supporting the overall sustainability goals of construction projects.

Leading Wood Plastic Composite Brands

Advanced Environmental Recycling Technologies, Inc. (AERT)
Axion Structural Innovations LLC
Beologic N.V.
CertainTeed Corporation
Fiberon, LLC
Fkur Kunststoff GmbH
Guangzhou Kingwood Co. Ltd.
Jelu-Werk Josef Ehrler GmbH & Co. KG
Woodmass
PolyPlank AB
Renolit
TAMKO Building Products, Inc.
TimberTech
Trex Company, Inc.
Universal Forest Product

About Future Market Insights (FMI)

Contact Us:

Global Aramid Fiber Market: Key Growth Drivers and Emerging Opportunities Across Industries

The global aramid fiber market, valued at approximately USD 4 billion in 2023, is poised for steady growth, with an anticipated CAGR of 5.5% through 2033. This growth is driven by increasing demand across diverse sectors such as aerospace, automotive, and defense, where aramid fibers are valued for their high strength, heat resistance, and lightweight properties. Additionally, the rising focus on sustainability and advancements in fiber technology are expected to further propel the market, positioning it as a crucial material in emerging applications like renewable energy and protective gear.

Growing remodeling efforts, as well as stringent rules governing workplace security and health in a variety of industries, are expected to boost the United States aramid fiber market opportunities. Such measures are also projected to contribute to the expansion of global aramid fiber adoption trends in Latin American countries.

Aramid fibers are important in sustainable energy usage, especially wind turbine blades. The requirement for durable and lightweight materials grows in tandem with the growth of the renewable energy sector.

The automobile and aerospace sectors in the United States are still looking for lightweight materials to increase fuel efficiency while lowering pollution. Aramid fibers are employed in a variety of components, which contributes to market growth.

Aramid fibers are also employed in the construction industry for purposes such as strengthening concrete. Infrastructure projects in the United States may increase demand for these materials.

In areas such as aircraft and automotive, the United States maintains high regulatory expectations for safety and quality. Compliance with these criteria is expected to remain a top priority for aramid fiber makers.

There are over 2,300 businesses in the German aerospace industry, most of which are concentrated in northern Germany. As a result, during the predicted period, aramid fiber consumption is expected to rise along with the growth in aircraft production. It is predicted that the market in this country is assumed to expand over the coming years due to the increasing demand from various end-user sectors.

Key Takeaways

The United States is predicted to reach US$ 900 million by 2033.
Germany’s aramid fiber market size is expected to reach US$ 780 million by the end of this forecast period.
China’s aramid fiber market is anticipated to be worth US$ 850 million.
China’s market is expected to exhibit a 5.2% CAGR until 2033.
The aramid fiber market in Japan is expected to develop significantly, reaching US$ 610 million by 2033.
The market for aramid fiber in South Korea is projected to develop at a CAGR of 4.1% from 2023 to 2033.
A market valuation of US$ 530 million is anticipated in South Korea at the conclusion of the forecasted period.
Based on application, the security and protection category is expected to lead sales and experience a CAGR of 4.8% through 2033.

“The increasing demand for aramid fiber from a wide range of industries, including the petroleum industry, healthcare services, manufacturing, and others, is predicted to fuel the target market’s growth from 2023 to 2033,” says an FMI analyst.

Shape Your Strategy with In-Depth Insights from the Aramid Fiber Market Report!

Competitive Landscape

The top companies in the global aramid fiber market are using tactics such as collaboration contracts, technological collaboration, and resource mobilization to strengthen their positions in this industry. Many global aramid fiber firms are likewise aiming to launch products that are both affordable and of high quality to increase market penetration.

In June 2022, Teijin Aramid B.V. launched the Woven Matrix concept to allow the creation of different ballistic protection choices. The woven matrix is made from Twaron, the organization’s efficient para-aramid.
Taekwang Industry announced a US$ 112 million budget proposal in May 2022 to enhance aromatic polyamide (aramid) production from 1,500 tons per year to 5,000 tons by 2025.

Top Key Players in the Global Market

Teijin Ltd.
Yantai Tayho Advanced Materials Co
E. I. du Pont de Nemours and Company (DowDuPont)
Hyosung & Hyosung Corp.
Toray Chemicals South Korea, Inc.
Kermel S.A.
Kolon Industries, Inc.
Huvis Corp.
China National Bluestar (Group) Co., Ltd.
SRO Aramid (Jiangzu) Co., Ltd.

Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global aramid fiber market presenting a historical analysis from 2018 to 2022 and forecast statistics between 2023 and 2033.

The study reveals essential insights by Product Type (Para-Aramid, Meta-Aramid), Application (Security & Protection, Frictional Materials, Rubber Reinforcement, Optical Fibers, Tire Reinforcement, Electrical Insulation, Aerospace, Others), and Region.

About Future Market Insights (FMI)

Contact Us: